Business
Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Cytokinetics to Host Investor/Media Event and Webcast Related to
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session\n Cytokinetics to Host Investor/Media Event and Webcast Related to GALACTIC-HF Results on November 13, 2020 at 1:00 PM ET SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six presentations at the American Heart Association (AHA) Scientific Sessions 2020, taking place online from November 13, 2020 – November 17, 2020, including the presentation of primary results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, in a Late Breaking Clinical Trial session, as well as five poster presentations. Results from GALACTIC-HF, one of the largest heart failure trials ever conducted, will be presented at a live, virtual, embargoed AHA News Briefing on Thursday, November 12, 2020 from 1:30-2:30 PM CT. Late Breaking Clinical Trial Session Title: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) Trial Session: LBS.01 - Heart Failure and Atrial Fibrillation: Vitamins, Minerals, Nutrients, and MoreSpeaker: John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HFDate: November 13, 2020Presentation Time: 10:35 – 10:45 AM CT Cytokinetics Investor/Media Event Cytokinetics will host an investor/media event related to the results of GALACTIC-HF on November 13, 2020 at 1:00 PM ET that will be simultaneously webcast and can be accessed at https://wsw.com/webcast/cc/cytk/1388034 or by visiting the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com. An archived replay of the virtual event will be available via Cytokinetics’ website until November 13, 2021. Members of Cytokinetics’ senior management will be joined by the following physician experts: John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GA...